Published in Cancer Res on October 15, 1997
EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors | NCT01251926
Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy | NCT00347698
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia (2001) 4.22
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol (2010) 3.40
Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med (2001) 3.02
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol (2007) 2.92
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A (2001) 2.81
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A (2002) 2.45
Enhanced antibody half-life improves in vivo activity. Nat Biotechnol (2010) 2.33
Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys (2011) 2.18
Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res (2007) 2.13
VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer (2008) 2.09
Outcome of a workshop on applications of protein models in biomedical research. Structure (2009) 2.05
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) (2011) 2.05
Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer (2012) 1.90
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A (2007) 1.73
Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res (2010) 1.71
VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A (2007) 1.68
Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest (2003) 1.66
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol (2015) 1.63
Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol (2009) 1.60
Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis (2004) 1.53
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol (2006) 1.48
Mural cell associated VEGF is required for organotypic vessel formation. PLoS One (2009) 1.48
Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med (2010) 1.45
The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs (2011) 1.41
Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer (2001) 1.41
Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci (2011) 1.39
Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol (2007) 1.35
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res (2008) 1.35
Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer (2005) 1.31
The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development. Nephron Physiol (2008) 1.24
Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia (2014) 1.23
Breast tumour angiogenesis. Breast Cancer Res (2007) 1.22
Angiogenesis in epithelian ovarian cancer. Mol Pathol (2002) 1.21
A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis (2009) 1.20
A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res (2009) 1.19
Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int (2014) 1.18
Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development. Protein Cell (2013) 1.18
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol (2014) 1.18
New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle (2010) 1.16
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma (2009) 1.14
Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res (2011) 1.14
Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol (2009) 1.13
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2011) 1.13
Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One (2011) 1.11
Targeting the tumor microenvironment: focus on angiogenesis. J Oncol (2011) 1.09
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res (2009) 1.08
Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis. Crit Care (2013) 1.08
Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy. World J Gastroenterol (2001) 1.07
Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets (2010) 1.07
Vascular endothelial growth factor a inhibition in gastric cancer. Gastric Cancer (2014) 1.07
Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer (2000) 1.07
Immunotherapy of cancer. Eur J Pharmacol (2009) 1.05
Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol (2008) 1.05
Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology (2009) 1.03
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci (2003) 1.03
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol (2011) 1.03
Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther (2010) 1.02
Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol (2013) 1.02
Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn J Ophthalmol (2010) 1.02
Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies. BMC Cancer (2009) 1.01
Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int J Mol Sci (2011) 1.01
Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones. Proc Natl Acad Sci U S A (2010) 1.00
Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One (2012) 1.00
Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist (2010) 1.00
Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. Int J Mol Sci (2015) 0.99
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging (2013) 0.99
Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration. Drug Des Devel Ther (2013) 0.99
Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma. Semin Hematol (2008) 0.98
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs (2012) 0.98
[Renal cell carcinoma 2008. Histopathology, molecular genetics and new therapeutic options]. Pathologe (2008) 0.98
The INNs and outs of antibody nonproprietary names. MAbs (2016) 0.97
Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol (2011) 0.97
Novel therapies in glioblastoma. Neurol Res Int (2012) 0.97
Treatment of age-related macular degeneration: focus on ranibizumab. Clin Ophthalmol (2008) 0.96
Angiopoietin-4 inhibits angiogenesis and reduces interstitial fluid pressure. Neoplasia (2006) 0.96
Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist (2011) 0.96
Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol (2003) 0.96
Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol (2007) 0.96
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer (2009) 0.96
Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res (2008) 0.95
Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma. J Mol Med (Berl) (2012) 0.94
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res (2015) 0.94
Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol (2010) 0.94
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression. Cancer Chemother Pharmacol (2014) 0.93
A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA. PLoS Med (2008) 0.93
What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol (1998) 0.93
Immunotherapy of head and neck cancer: current and future considerations. J Oncol (2009) 0.93
Notch signaling in developmental and tumor angiogenesis. Genes Cancer (2011) 0.93
Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med (2008) 0.92
Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers. Mol Pharm (2010) 0.92
Anti-angiogenesis approach to genitourinary cancer treatment. Update Cancer Ther (2009) 0.92
Drugs derived from phage display: from candidate identification to clinical practice. MAbs (2014) 0.91
Total chemical synthesis of biologically active vascular endothelial growth factor. Angew Chem Int Ed Engl (2011) 0.91
Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis. Oncologist (2014) 0.91
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 16.92
Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature (2004) 16.76
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care (2001) 9.76
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med (1999) 9.18
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
Role of domestic ducks in the propagation and biological evolution of highly pathogenic H5N1 influenza viruses in Asia. Proc Natl Acad Sci U S A (2005) 7.12
VEGF is required for growth and survival in neonatal mice. Development (1999) 6.16
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A (1995) 5.92
Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature (1995) 5.91
Are ducks contributing to the endemicity of highly pathogenic H5N1 influenza virus in Asia? J Virol (2005) 5.78
Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell (1998) 5.78
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
Genetic diversity and disease control in rice. Nature (2000) 5.34
High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem (2000) 5.18
Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels. Cell (2000) 5.08
Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell (1999) 5.07
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 5.04
Crystal structure of a TFIIB-TBP-TATA-element ternary complex. Nature (1995) 4.93
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem (1992) 4.92
NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol (2000) 4.75
Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci U S A (2006) 4.49
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem (1994) 4.41
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell (1993) 4.33
A transcriptional switch mediated by cofactor methylation. Science (2001) 4.32
Superconductivity at 43 K in SmFeAsO1-xFx. Nature (2008) 3.80
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem (1998) 3.78
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Generation of coated intermediates of clathrin-mediated endocytosis on protein-free liposomes. Cell (1998) 3.62
Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam. Virology (2006) 3.59
Sequence-specific RNA binding by a Nova KH domain: implications for paraneoplastic disease and the fragile X syndrome. Cell (2000) 3.59
Synaptic vesicle endocytosis impaired by disruption of dynamin-SH3 domain interactions. Science (1997) 3.59
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest (1995) 3.52
Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol (2005) 3.51
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med (1997) 3.48
Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature (2001) 3.42
Structural characterization and biological functions of fibroblast growth factor. Endocr Rev (1987) 3.40
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res (2000) 3.39
Prevalence and genetic diversity of coronaviruses in bats from China. J Virol (2006) 3.37
A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell (1999) 3.36
Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature (1997) 3.14
The genesis and evolution of H9N2 influenza viruses in poultry from southern China, 2000 to 2005. J Virol (2007) 3.12
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling. Oncogene (2011) 3.08
Plasma urate and risk of Parkinson's disease. Am J Epidemiol (2007) 3.06
Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A (1993) 3.01
Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem (1997) 2.95
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol (1996) 2.95
Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem (2000) 2.87
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77
The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem (1996) 2.75
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol (1994) 2.66
Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med (1998) 2.64
The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol (1991) 2.63
The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev (1998) 2.58
Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding. Nature (2000) 2.57
Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol Endocrinol (1997) 2.51
Phenotypes Associated with SHOX Deficiency. J Clin Endocrinol Metab (2001) 2.51
Evolution and molecular epidemiology of H9N2 influenza A viruses from quail in southern China, 2000 to 2005. J Virol (2006) 2.47
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun (1992) 2.47
Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development (2000) 2.43
Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem (2001) 2.42
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology (1996) 2.41
Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene (2011) 2.36
Infection of immunocompromised patients by avian H9N2 influenza A virus. J Infect (2011) 2.29
An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature (1997) 2.29
Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem (1995) 2.28
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst (2001) 2.27
Establishment of influenza A virus (H6N1) in minor poultry species in southern China. J Virol (2007) 2.26
Ribonuclease-resistant RNA controls (Armored RNA) for reverse transcription-PCR, branched DNA, and genotyping assays for hepatitis C virus. Clin Chem (1999) 2.26
Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun (1991) 2.25
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol (2000) 2.25
Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards. J Clin Microbiol (1998) 2.23
Colloid cyst of the third ventricle: imaging-pathologic correlation. AJNR Am J Neuroradiol (2000) 2.23
Two-dimensional imaging through diffusing media using 150-fs gated electronic holography techniques. Opt Lett (1991) 2.21
A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. Nat Neurosci (2000) 2.20
Rapid cloning by homologous recombination in vivo. Nucleic Acids Res (1993) 2.19
Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest (1992) 2.19
Nitrogen fixation ability of exopolysaccharide synthesis mutants of Rhizobium sp. strain NGR234 and Rhizobium trifolii is restored by the addition of homologous exopolysaccharides. J Bacteriol (1987) 2.17
Evolutionary insights into the ecology of coronaviruses. J Virol (2007) 2.16
Crystal structure of a human TATA box-binding protein/TATA element complex. Proc Natl Acad Sci U S A (1996) 2.15
Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol (1992) 2.14
Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells. J Biol Chem (1998) 2.13
Squeezing axons out of the gray matter: a role for slit and semaphorin proteins from midline and ventral spinal cord. Cell (2000) 2.11
VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest (1999) 2.08
Endoscopic closure of esophageal intrathoracic leaks: stent versus endoscopic vacuum-assisted closure, a retrospective analysis. Endoscopy (2013) 2.08
Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med (1999) 2.07
Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation (1995) 2.07
Identification and characterization of the mouse obesity gene tubby: a member of a novel gene family. Cell (1996) 2.04
The development and genetic diversity of H5N1 influenza virus in China, 1996-2006. Virology (2008) 2.04
Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate (1998) 2.02
Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res (2000) 2.02
Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum (1998) 2.00